معرفی
David Jayne is a Professor of Clinical Autoimmunity at the University of Cambridge and Director of the Vasculitis and Lupus Service at Addenbrooke’s Hospital. His work bridges clinical practice and translational research, focusing on autoimmune diseases with a particular emphasis on ANCA-associated vasculitis (AAV), lupus, and immune-mediated renal disease. As founder and President of the European Vasculitis Society, he coordinates international clinical research networks like EUVAS.
- Education:
- University of Cambridge
- University of London
- Harvard Medical School
- Affiliations:
- Cambridge Immunology Network
- Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID)
- Department of Medicine, University of Cambridge
- Cambridge University Hospitals
His research explores immunotherapy strategies for autoimmune diseases, including anti-CD40 monoclonal antibodies and complement inhibitors like avacopan. Recent work examines glucocorticoid-sparing therapies, B cell targeting, and real-world evidence for long-term disease management. His clinical trials methodology emphasizes multi-center collaboration and patient stratification by disease severity.
Publications reveal a focus on
- ANCA-Associated Vasculitis
- Eosinophilic Granulomatosis with Polyangiitis (EGPA)
- Lupus Nephritis
- Complement Pathway Modulation
- Interleukin-5 Inhibition
- Long-Term Disease Monitoring
Professional memberships include the Renal Association, European Renal Association, and American Society on Nephrology. Notably, he chairs the European Vasculitis Society and contributes to international guideline development for AAV management.
As a clinician-researcher, he integrates acute nephrology, transplantation, and internal medicine into his clinical practice while leading studies on immunotherapeutic agents for rare autoimmune conditions. His team investigates type I interferon blockade and proteomic changes following targeted therapies.
